AT-511: Clinical Trials

2 trials of AT-511, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Terminated 1

Follow AT-511: new trials by email Literature Review of AT-511 trials Research Report on AT-511

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Bemnifosbuvir (BEM), Placebo - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
Phase 3CompletedAtea Pharmaceuticals, Inc.22852022-11-252025-06-13
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
RO7496998, Placebo - COVID-19
Phase 3TerminatedHoffmann-La Roche2162021-04-282024-01-05

Conditions studied

COVID-19 (2)

Sponsors

Atea Pharmaceuticals, Inc. (1)  ·  Hoffmann-La Roche (1)

Countries

Argentina (2)  ·  Brazil (2)  ·  Germany (2)  ·  Japan (2)  ·  Mexico (2)  ·  Romania (2)  ·  Turkey (Türkiye) (2)  ·  Belgium (1)  ·  Canada (1)  ·  Denmark (1)  ·  India (1)  ·  Latvia (1)  ·  Netherlands (1)  ·  Pakistan (1)  ·  Philippines (1)

Results publications

PMID 37928891